Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 9, 2010, Pages 3026-3035

  Zhang, Peng ^a   Zou, Mu Fa ^a   Rodriguez, Alice L ^b   Jeffrey Conn, P ^b   Newman, Amy Hauck ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug abuse; Metabotropic glutamate receptor subtype 5; mGluR5; MPEP; MTEP

Indexed keywords

2 (4 FLUOROPHENYL) 4 (2 METHYLBENZO[D]THIAZOL 5 YL)BENZONITRILE; 2 (PYRIDIN 3 YL) 4 (2 METHYLBENZO[D]THIAZOL 5 YL)BENZONITRILE; 2 BENZOXY 5 (2 METHYLBENZO[D]THIAZOL 5 YL)BENZONITRILE; 2 BENZOXY 5 (2 METHYLQUINOLIN 7 YL)BENZONITRILE; 2 BENZOXY 5 BROMOBENZONITRILE; 2 BROMO 5 CHLOROBENZONITRILE; 2 CYANO 4 (2 METHYLBENZO[D]THIAZOL 5 YL)PHENYLTRIFLATE; 2 CYANO 4 (2 METHYLQUINOLIN 7 YL)PHENYLTRIFLATE; 2 HYDROXY 5 (2 METHYLBENZO[D]THIAZOL 5YL)BENZONITRILE; 2 HYDROXY 5 (2 METHYLQUINOLIN 7 YL)BENZONITRILE; 2 METHOXYMETHOXY 5 (2 METHYLQUINOLIN 7 YL)BENZONITRILE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 2 METHYL 6 [(TRIMETHYLSILANYL)ETHYNYL]PYRIDINE; 2 PHENYL 4 (2 METHYLBENZO[D]THIAZOL 5 YL)BENZONITRILE; 5 (2 METHYLQUINOLIN 7 YL) 2 (4 FLUOROPHENYL)BENZONITRILE; 5 (2 METHYLQUINOLIN 7 YL) 2 (PYRIDIN 3 YL)BENZONITRILE; 5 (2 METHYLQUINOLIN 7 YL) 2 PHENYLBENZONITRILE; 5 (2 METHYLQUINOLIN 7 YL)NICOTINONITRILE; 5 [(6 METHYLPYRIDIN 2 YL)ETHYNYL]NICOTINONITRILE; 5 BROMO 2 CHLORONICOTINONITRILE; 5 BROMO 2 METHOXYMETHOXYLBENZONITRILE; 5 CHLORO 2 (2 METHYLQUINOLIN 7 YL)BENZONITRILE; 5 CHLORO 2 (4 FLUOROPHENYL)BENZONITRILE; 5 CHLORO 2 (PYRIDIN 3 YL)BENZONITRILE; 5 CHLORO 2 PHENYLBENZONITRILE; BENZOTHIAZOLE DERIVATIVE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; NONHUMAN; PHARMACOPHORE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOTHIAZOLES; BRAIN; CELL LINE; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PYRIDINES; QUINOLINES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77951205576     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.03.053     Document Type: Article

References (29)

1. Jaescheke G.W.J.G., Nordquist R.E., and Spooren W. Expert Opin. Ther. Patents 18 (2008) 123
2. Lindsley C.W., and Emmitte K.A. Curr. Opin. Drug Disc. Dev. 12 (2009) 446
3. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., Corsi M., Orzi F., and Conquet F. Nat. Neurosci. 4 (2001) 873
4. Kenny P.J., and Markou A. Trends Pharmacol. Sci. 25 (2004) 265
5. Lee B., Platt D.M., Rowlett J.K., Adewale A.S., and Spealman R.D. J. Pharmacol. Exp. Ther. 312 (2005) 1232
6. Platt D.M., Rowlett J.K., and Spealman R.D. Psychopharmacology (Berl) 200 (2008) 167
7. Carroll F.I. Ann. N.Y. Acad. Sci. 1141 (2008) 221
8. Brauner-Osborne H., Wellendorph P., and Jensen A.A. Curr. Drug Targets 8 (2007) 169
9. Bridges T.M., and Lindsley C.W. ACS Chem. Biol. 3 (2008) 530
10. Pagano A., Ruegg D., Litschig S., Stoehr N., Stierlin C., Heinrich M., Floersheim P., Prezeau L., Carroll F., Pin J.P., Cambria A., Vranesic I., Flor P.J., Gasparini F., and Kuhn R. J. Biol. Chem. 275 (2000) 33750
11. Bach P., Nilsson K., Wallberg A., Bauer U., Hammerland L.G., Peterson A., Svensson T., Osterlund K., Karis D., Boije M., and Wensbo D. Bioorg. Med. Chem. Lett. 16 (2006) 4792
12. Bach P., Nilsson K., Svensson T., Bauer U., Hammerland L.G., Peterson A., Wallberg A., Osterlund K., Karis D., Boije M., and Wensbo D. Bioorg. Med. Chem. Lett. 16 (2006) 4788
13. Wendt J.A., Deeter S.D., Bove S.E., Knauer C.S., Brooker R.M., Augelli-Szafran C.E., Schwarz R.D., Kinsora J.J., and Kilgore K.S. Bioorg. Med. Chem. Lett. 17 (2007) 5396
14. Milbank J.B., Knauer C.S., Augelli-Szafran C.E., Sakkab-Tan A.T., Lin K.K., Yamagata K., Hoffman J.K., Zhuang N., Thomas J., Galatsis P., Wendt J.A., Mickelson J.W., Schwarz R.D., Kinsora J.J., Lotarski S.M., Stakich K., Gillespie K.K., Lam W.W., and Mutlib A.E. Bioorg. Med. Chem. Lett. 17 (2007) 4415
15. Galatsis P., Yamagata K., Wendt J.A., Connolly C.J., Mickelson J.W., Milbank J.B., Bove S.E., Knauer C.S., Brooker R.M., Augelli-Szafran C.E., Schwarz R.D., Kinsora J.J., and Kilgore K.S. Bioorg. Med. Chem. Lett. 17 (2007) 6525
16. Kulkarni S.S., and Newman A.H. Bioorg. Med. Chem. Lett. 17 (2007) 2987
17. Kulkarni S.S., and Newman A.H. Bioorg. Med. Chem. Lett. 17 (2007) 2074
18. Kulkarni S.S., Nightingale B., Dersch C.M., Rothman R.B., and Newman A.H. Bioorg. Med. Chem. Lett. 16 (2006) 3371
19. Kulkarni S.S., Zou M.F., Cao J., Deschamps J.R., Rodriguez A.L., Conn P.J., and Newman A.H. J. Med. Chem. 52 (2009) 3563
20. Alagille D., Baldwin R.M., Roth B.L., Wroblewski J.T., Grajkowska E., and Tamagnan G.D. Bioorg. Med. Chem. Lett. 15 (2005) 945
21. Alagille D., Baldwin R.M., Roth B.L., Wroblewski J.T., Grajkowska E., and Tamagnan G.D. Bioorg. Med. Chem. 13 (2005) 197
22. Boice G.N., Savarin C.G., Murry J.A., Conrad K., Matty L., Corley E.G., Smitrovich J.H., and Hughes D. Tetrahedron 60 (2004) 11367
23. Witherington J., Bordas V., Garland S.L., Hickey D.M., Ife R.J., Liddle J., Saunders M., Smith D.G., and Ward R.W. Bioorg. Med. Chem. Lett. 13 (2003) 1577
24. PDSP http://pdsp.med.unc.edu/indexR.html, NIMH Psychoactive Drug Screening Program, 2009.
25. Busse C.S., Brodkin J., Tattersall D., Anderson J.J., Warren N., Tehrani L., Bristow L.J., Varney M.A., and Cosford N.D. Neuropsychopharmacology 29 (2004) 1971
26. MacroModel; Maestro using the default setting of commond 'flexible ligand alignment'. 9.6; 8.5; Schrödinger, LLC.: New York, NY, 2008.
27. Sharma S., Kedrowski J., Rook J.M., Smith R.L., Jones C.K., Rodriguez A.L., Conn P.J., and Lindsley C.W. J. Med. Chem. 52 (2009) 4103
28. Sharma S., Rodriguez A.L., Conn P.J., and Lindsley C.W. Bioorg. Med. Chem. Lett. 18 (2008) 4098
29. ATDP, The Addiction Treatment Discovery Program, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, 2009.